Palatin Technologies, Inc. (LSE: 0KF3)
Health Care · Biotechnology · US
$9.69
-6.83% today · -3.3% 1Y
Palatin Technologies, Inc. (LSE: 0KF3) operates in the Biotechnology industry within the Health Care sector. The company is valued at $17.24M and employs 29 people.
Over the last twelve months the share price has lost 3.3%, trading between 5.75 and 27.71.
Tweenvest scores Palatin Technologies, Inc. across four factors: quality 24/100, value 70/100. Its strongest factor is value.
0KF3 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $17.24M
- Revenue (TTM)
- $12.88M
- P/E
- —
- EPS
- -3.04
- Dividend yield
- —
- Beta (5Y)
- -0.10
- 52-week high
- $27.71
- 52-week low
- $5.75
- Avg volume (3M)
- —
- Shares outstanding
- 1.78M
- Employees
- 29
- Next earnings
- —
About Palatin Technologies, Inc.
Palatin Technologies, Inc., established in Cranbury, New Jersey, in 1986, is a biopharmaceutical company focused on developing specialized, receptor-targeting therapeutics for various medical conditions within the United States. The firm's flagship product, Vyleesi, is an approved melanocortin receptor (MCr) agonist designed to treat hypoactive sexual desire disorder in premenopausal women. Beyond Vyleesi, Palatin's robust pipeline features several investigational compounds: Oral PL8177: A selective MC1r agonist peptide that has successfully completed Phase I clinical trials for the treatment of inflammatory bowel diseases. PL9643: A peptide melanocortin agonist active at multiple melanocortin receptors, including MC1r and MC5r, being developed for anti-inflammatory ocular conditions such as dry eye disease. Additionally, the company is exploring other melanocortin peptides for diabetic retinopathy. PL3994: A synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide and a natriuretic peptide receptor (NPR)-A agonist, intended for cardiovascular applications. PL5028: An NPR-A and NPR-binder under development to address cardiovascular and fibrotic diseases, including the reduction of cardiac hypertrophy and fibrosis.
- ISIN
- US6960776010
- Founded
- 1986
- Listed since
- Jan 29, 2018
- Exchange
- London Stock Exchange
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.